MannKind Corporation MNKD
4.07 USD 0.00 (+0.00%)
Regular-session close
4.02 -0.05 -1.23%
After hours · Nov 18, 7:36 PM ET
4.03 Day range 4.17
2.23 52-week range 6.51
- YTD
- -28.22%
- 1 year
- -19.57%
News
marketbeat.com MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction MannKind NASDAQ: MNKD expects to be profitable and report record revenue in the fourth quarter as it builds on the launch of FUROSCIX ReadyFlow and the pediatric approval of inhaled insulin Afrezza,…
marketbeat.com MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations MannKind NASDAQ: MNKD is focusing on the launch of its FUROSCIX ReadyFlow autoinjector, pediatric AFREZZA and the development of inhaled nintedanib, CEO Michael Castagna said at the UBS Biopharma…
seekingalpha.com MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com MannKind's ReadyFlow Launch Keeps The Bull Case Alive MNKD's ReadyFlow could widen Furoscix's reach into more outpatient settings, which I consider a promising value driver in the long run. Also, their pediatric launch expands Afrezza's market. The main…benzinga.com RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $5 RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Sector Perform and raises the price target from $4.75 to $5.
benzinga.com Cantor Fitzgerald Maintains Overweight on MannKind, Raises Price Target to $10 Cantor Fitzgerald analyst Olivia Brayer Saunders maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $8 to $10.
seekingalpha.com MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
defenseworld.net MannKind Q3 Earnings Call Highlights MannKind (NASDAQ: MNKD) expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza…
marketbeat.com MannKind Q3 Earnings Call Highlights MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza…
zacks.com Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates MannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.
globenewswire.com MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after…
marketbeat.com MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF,…benzinga.com Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
benzinga.com This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.benzinga.com Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10 Chardan Capital analyst Andreas Argyrides initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $10.
globenewswire.com MannKind to Participate in the Chardan Healthcare Conference DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a…
globenewswire.com MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across…
marketbeat.com MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major…
benzinga.com Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.
globenewswire.com MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential…
globenewswire.com MannKind to Present at Upcoming Investor Conferences DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
zacks.com FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
seekingalpha.com MannKind: New Approvals Majorly Increase MannKind's Prospects Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity…
